Amneal Interest Income from 2010 to 2025

AMRX Stock

USD 8.67 0.22 2.47%

Amneal Pharmaceuticals, Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income will likely drop to about 103.3 M in 2025. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2010-12-31

Previous Quarter

199.1 M

Current Value

103.3 M

Quarterly Volatility

67.5 M

Credit Downgrade

Yuan Drop

Covid

Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 164.4 M, Interest Expense of 134.8 M or Selling General Administrative of 303.3 M, as well as many indicators such as Price To Sales Ratio of 0.83, Dividend Yield of 0.096 or Days Sales Outstanding of 132. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.

Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Interest Income Growth Pattern

Below is the plot of the Interest Income of Amneal Pharmaceuticals, Class over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Amneal Pharmaceuticals,'s Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Amneal Interest Income Regression Statistics

	Arithmetic Mean	103,795,323
	Geometric Mean	81,918,637
	Coefficient Of Variation	64.99
	Mean Deviation	62,710,224
	Median	103,289,120
	Standard Deviation	67,459,173
	Sample Variance	4550.7T
	Range	159.9M
	R-Value	0.81
	Mean Square Error	1652.4T
	R-Squared	0.66
	Significance	0.0001
	Slope	11,520,693
	Total Sum of Squares	68261.1T

Amneal Interest Income History

	2025	103.3 M
	2024	199.1 M
	2019	173.2 M
	2018	163.3 M
	2017	53.4 M
	2016	40.4 M

Other Fundumenentals of Amneal Pharmaceuticals,

Net Interest Income

Amneal Pharmaceuticals, Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.83	-0.95	0.78	-0.34	0.7	0.91	0.83	0.92	-0.79	0.93	0.67	0.94	0.35	0.9	0.23	0.42	0.95	0.86	0.73	0.62	0.96	0.76	0.29	-0.2
Total Stockholder Equity	0.83		-0.78	0.75	0.18	0.77	0.74	0.5	0.64	-0.58	0.72	0.24	0.71	-0.11	0.64	-0.14	-0.05	0.9	0.55	0.59	0.17	0.8	0.83	-0.07	0.13
Net Tangible Assets	-0.95	-0.78		-0.83	0.47	-0.74	-0.98	-0.89	-0.94	0.9	-0.98	-0.73	-0.98	-0.44	-0.94	-0.26	-0.52	-0.97	-0.92	-0.87	-0.7	-0.99	-0.74	-0.37	0.26
Net Debt	0.78	0.75	-0.83		-0.2	0.53	0.86	0.68	0.76	-0.81	0.78	0.48	0.8	0.02	0.73	-0.25	0.18	0.83	0.61	0.73	0.44	0.81	0.8	-0.07	0.25
Retained Earnings	-0.34	0.18	0.47	-0.2		-0.12	-0.5	-0.7	-0.58	0.59	-0.53	-0.84	-0.55	-0.88	-0.59	-0.68	-0.91	-0.26	-0.7	-0.55	-0.85	-0.42	0.07	-0.71	0.65
Accounts Payable	0.7	0.77	-0.74	0.53	-0.12		0.66	0.48	0.54	-0.6	0.68	0.3	0.64	0.18	0.54	0.21	0.18	0.8	0.59	0.71	0.24	0.68	0.44	0.16	-0.18
Long Term Debt	0.91	0.74	-0.98	0.86	-0.5	0.66		0.92	0.94	-0.95	0.97	0.76	0.98	0.44	0.95	0.23	0.53	0.94	0.91	0.92	0.7	0.97	0.75	0.35	-0.24
Net Receivables	0.83	0.5	-0.89	0.68	-0.7	0.48	0.92		0.95	-0.88	0.95	0.93	0.95	0.61	0.97	0.48	0.68	0.8	0.92	0.85	0.86	0.88	0.58	0.45	-0.37
Good Will	0.92	0.64	-0.94	0.76	-0.58	0.54	0.94	0.95		-0.84	0.97	0.88	0.98	0.54	0.98	0.37	0.63	0.87	0.93	0.78	0.8	0.94	0.65	0.41	-0.29
Short Term Investments	-0.79	-0.58	0.9	-0.81	0.59	-0.6	-0.95	-0.88	-0.84		-0.9	-0.75	-0.91	-0.47	-0.89	-0.27	-0.55	-0.83	-0.85	-0.95	-0.7	-0.87	-0.65	-0.36	0.27
Long Term Debt Total	0.93	0.72	-0.98	0.78	-0.53	0.68	0.97	0.95	0.97	-0.9		0.83	0.99	0.5	0.98	0.37	0.57	0.93	0.92	0.88	0.74	0.96	0.68	0.36	-0.27
Capital Surpluse	0.67	0.24	-0.73	0.48	-0.84	0.3	0.76	0.93	0.88	-0.75	0.83		0.83	0.76	0.88	0.65	0.82	0.58	0.84	0.71	0.88	0.7	0.3	0.51	-0.45
Total Liab	0.94	0.71	-0.98	0.8	-0.55	0.64	0.98	0.95	0.98	-0.91	0.99	0.83		0.52	0.99	0.35	0.6	0.93	0.94	0.87	0.76	0.97	0.7	0.4	-0.3
Short Long Term Debt	0.35	-0.11	-0.44	0.02	-0.88	0.18	0.44	0.61	0.54	-0.47	0.5	0.76	0.52		0.57	0.83	0.98	0.26	0.72	0.48	0.68	0.41	-0.16	0.86	-0.84
Total Current Assets	0.9	0.64	-0.94	0.73	-0.59	0.54	0.95	0.97	0.98	-0.89	0.98	0.88	0.99	0.57		0.43	0.64	0.87	0.94	0.84	0.8	0.94	0.68	0.43	-0.35
Treasury Stock	0.23	-0.14	-0.26	-0.25	-0.68	0.21	0.23	0.48	0.37	-0.27	0.37	0.65	0.35	0.83	0.43		0.73	0.13	0.52	0.33	0.51	0.23	-0.23	0.66	-0.8
Short Term Debt	0.42	-0.05	-0.52	0.18	-0.91	0.18	0.53	0.68	0.63	-0.55	0.57	0.82	0.6	0.98	0.64	0.73		0.33	0.77	0.54	0.74	0.49	-0.07	0.8	-0.73
Intangible Assets	0.95	0.9	-0.97	0.83	-0.26	0.8	0.94	0.8	0.87	-0.83	0.93	0.58	0.93	0.26	0.87	0.13	0.33		0.84	0.81	0.55	0.97	0.81	0.25	-0.16
Common Stock	0.86	0.55	-0.92	0.61	-0.7	0.59	0.91	0.92	0.93	-0.85	0.92	0.84	0.94	0.72	0.94	0.52	0.77	0.84		0.82	0.83	0.92	0.52	0.68	-0.58
Property Plant Equipment	0.73	0.59	-0.87	0.73	-0.55	0.71	0.92	0.85	0.78	-0.95	0.88	0.71	0.87	0.48	0.84	0.33	0.54	0.81	0.82		0.62	0.82	0.55	0.36	-0.31
Current Deferred Revenue	0.62	0.17	-0.7	0.44	-0.85	0.24	0.7	0.86	0.8	-0.7	0.74	0.88	0.76	0.68	0.8	0.51	0.74	0.55	0.83	0.62		0.7	0.37	0.62	-0.52
Net Invested Capital	0.96	0.8	-0.99	0.81	-0.42	0.68	0.97	0.88	0.94	-0.87	0.96	0.7	0.97	0.41	0.94	0.23	0.49	0.97	0.92	0.82	0.7		0.78	0.41	-0.29
Net Working Capital	0.76	0.83	-0.74	0.8	0.07	0.44	0.75	0.58	0.65	-0.65	0.68	0.3	0.7	-0.16	0.68	-0.23	-0.07	0.81	0.52	0.55	0.37	0.78		-0.08	0.17
Capital Stock	0.29	-0.07	-0.37	-0.07	-0.71	0.16	0.35	0.45	0.41	-0.36	0.36	0.51	0.4	0.86	0.43	0.66	0.8	0.25	0.68	0.36	0.62	0.41	-0.08		-0.95
Long Term Investments	-0.2	0.13	0.26	0.25	0.65	-0.18	-0.24	-0.37	-0.29	0.27	-0.27	-0.45	-0.3	-0.84	-0.35	-0.8	-0.73	-0.16	-0.58	-0.31	-0.52	-0.29	0.17	-0.95

Click cells to compare fundamentals

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	199.1 M	103.3 M
Net Interest Income	-258.6 M	-245.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Interest Income from 2010 to 2025

Latest Amneal Pharmaceuticals,'s Interest Income Growth Pattern

Amneal Interest Income Regression Statistics

Amneal Interest Income History

Other Fundumenentals of Amneal Pharmaceuticals,

Amneal Pharmaceuticals, Interest Income component correlations

About Amneal Pharmaceuticals, Financial Statements

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY